- This event has passed.
ASCO 2024
May 31 @ 9:00 am - June 4 @ 3:00 pm
Join us at the ASCO annual conference
Rapid Oral Abstract
Title: First-in-human phase 1 clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).
Presenter: Dean Fennell
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Day/Time: Monday June 3, 9:06 am (session from 8:00-9:30 am)
Abstract #3019